Seragon names Tony Coles to board
This article was originally published in Scrip
San Diego-based Seragon Pharmaceuticals, a clinical-stage biotechnology company focused on the development of drugs for hormone-driven cancers, has named N Anthony (Tony) Coles to its board of directors. Most recently, Dr Coles was president, chief executive officer and chair of the board of Onyx Pharmaceuticals, a global biopharmaceutical company acquired by Amgen in October 2013. He is currently a member of the board of directors of McKesson Corporation, vice-chair of the board of trustees for Johns Hopkins University, and a member of the board of trustees for Johns Hopkins Medicine. Dr Coles is also a member of the board of the US Olympic and Paralympic Foundation.
You may also be interested in...
The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.